Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review

OBJECTIVES: Although many studies have reported on the cost-effectiveness of bosentan for treating pulmonary arterial hypertension (PAH), a systematic review of economic evaluations of bosentan is currently lacking. Objective evaluation of current pharmacoeconomic evidence can assist decision makers...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Ruxu, Qian, Xinyu, Tang, Weijing, Xie, Tian, Zeng, Fang, Chen, Jun, Zhang, Yu, Liu, Jinyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276424/
https://www.ncbi.nlm.nih.gov/pubmed/30581511
http://dx.doi.org/10.1155/2018/1015239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276424/
https://www.ncbi.nlm.nih.gov/pubmed/30581511
http://dx.doi.org/10.1155/2018/1015239

Ejemplares similares